Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus salivarius BL2201
- Development stage
- Unknown
- Lead developer
- BLIS Technologies
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus salivarius BL2201 is a specific probiotic bacterial strain, recently reclassified as Ligilactobacillus salivarius, developed by Blis Technologies. It is primarily utilized for its ability to support oral and upper respiratory health through the production of bacteriocins, specifically salivaricins, which exert targeted antimicrobial activity against common pathogens such as Streptococcus pyogenes and Streptococcus pneumoniae. By colonizing the oral mucosa, BL2201 provides a competitive exclusion mechanism that prevents the adhesion and proliferation of harmful bacteria. It is commonly incorporated into dietary supplements and oral health products aimed at reducing the incidence of throat infections, managing halitosis, and promoting a balanced oral microbiome.
- Other names
- Ligilactobacillus salivarius BL2201
02
Targets
IL10 (Interleukin-10)
Beyond the preview
Go deeper on Lactobacillus salivarius BL2201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus salivarius BL2201.